Trends in Use of Granulocyte Colony-Stimulating Factor Following Introduction of Biosimilars Among Adults With Cancer and Commercial or Medicare Insurance From 2014 to 2019
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Trends in Use of Granulocyte Colony-Stimulating Factor Following Introduction of Biosimilars Among Adults With Cancer and Commercial or Medicare Insurance From 2014 to 2019
Authors
Keywords
-
Journal
JAMA Network Open
Volume 4, Issue 11, Pages e2133474
Publisher
American Medical Association (AMA)
Online
2021-11-24
DOI
10.1001/jamanetworkopen.2021.33474
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Patient, nurse, and physician preferences: final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or on-body injector in cancer patients
- (2021) Michael Metz et al. SUPPORTIVE CARE IN CANCER
- Economic Analysis on Adoption of Biosimilar Granulocyte Colony-Stimulating Factors in Patients With Nonmyeloid Cancer at Risk of Febrile Neutropenia Within the Oncology Care Model Framework
- (2021) Weijia Wang et al. JCO Oncology Practice
- Primary Prophylaxis With Biosimilar Filgrastim for Patients at Intermediate Risk for Febrile Neutropenia: A Cost-Effectiveness Analysis
- (2021) Edward Li et al. JCO Oncology Practice
- Impact of a G-CSF Policy to Reduce Low-Value Care on Guideline Adherence and Mortality
- (2021) Chinelo C. Orji et al. JCO Oncology Practice
- Patterns of granulocyte colony–stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy
- (2020) Prasad L. Gawade et al. SUPPORTIVE CARE IN CANCER
- Biosimilar Uptake in Medicare Part B Varied Across Hospital Outpatient Departments and Physician Practices: The Case of Filgrastim
- (2020) Mariana P. Socal et al. VALUE IN HEALTH
- Cost-effectiveness of filgrastim-sndz as primary prophylaxis (PP) versus secondary prophylaxis (SP) to prevent chemotherapy-induced febrile neutropenia (FN) in breast cancer patients at intermediate risk.
- (2020) Edward C. Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Association Between Filgrastim Biosimilar Availability and Changes in Claim Payments and Patient Out-of-Pocket Costs for Biologic Filgrastim Products
- (2020) Morgane C. Mouslim et al. VALUE IN HEALTH
- Biosimilar Filgrastim Uptake And Costs Among Commercially Insured, Medicare Advantage
- (2019) Pinar Karaca-Mandic et al. HEALTH AFFAIRS
- A cost-effectiveness analysis of primary prophylaxis (PP) versus secondary prophylaxis (SP) with biosimilar myeloid growth factors (MGFs) for preventing chemotherapy-induced febrile neutropenia (FN) in non-Hodgkin lymphoma (NHL) patients at intermediate risk.
- (2019) Gary H. Lyman et al. JOURNAL OF CLINICAL ONCOLOGY
- Trends in the use of primary prophylactic colony-stimulating factors and neutropenia-related hospitalization in elderly cancer patients receiving myelosuppressive chemotherapy in the USA: 1995–2015
- (2019) Shuling Li et al. SUPPORTIVE CARE IN CANCER
- Real-World Impact of a Decision Support Tool on Colony-Stimulating Factor Use and Chemotherapy-Induced Febrile Neutropenia Among Patients With Breast Cancer
- (2018) Abiy Agiro et al. Journal of the National Comprehensive Cancer Network
- Estimation of The Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology
- (2018) John Marquart et al. JAMA Oncology
- Uptake of the Biologic Filgrastim and Its Biosimilar Product Among the Medicare Population
- (2018) Steven Kozlowski et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pharmacovigilance in oncology
- (2018) Paolo Baldo et al. International Journal of Clinical Pharmacy
- Appropriateness of granulocyte colony-stimulating factor use in patients receiving chemotherapy by febrile neutropenia risk level
- (2018) Hassam Baig et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Obstacles to the Adoption of Biosimilars for Chronic Diseases
- (2017) Aaron Hakim et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
- (2017) Jeffrey Crawford et al. Journal of the National Comprehensive Cancer Network
- Use of prophylactic growth factors and antimicrobials in elderly patients with cancer: a review of the Medicare database
- (2017) Romina Sosa et al. SUPPORTIVE CARE IN CANCER
- Reducing Overuse of Colony-Stimulating Factors in Patients With Lung Cancer Receiving Chemotherapy: Evidence From a Decision Support–Enabled Program
- (2017) Gboyega Adeboyeje et al. Journal of Oncology Practice
- Risk and Timing of Neutropenic Events in Adult Cancer Patients Receiving Chemotherapy: The Results of a Prospective Nationwide Study of Oncology Practice
- (2017) Jeffrey Crawford et al. Journal of the National Comprehensive Cancer Network
- Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor
- (2016) Derek Weycker et al. SUPPORTIVE CARE IN CANCER
- Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review
- (2013) Gary H. Lyman et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Comparison of Pegfilgrastim Prescribing Practice to National Guidelines at a University Hospital Outpatient Oncology Clinic
- (2013) Geralyn E. Waters et al. Journal of Oncology Practice
- Guideline-Based Peer-to-Peer Consultation Optimizes Pegfilgrastim Use With No Adverse Clinical Consequences
- (2012) Marc L. Fishman et al. Journal of Oncology Practice
- Use of Colony-Stimulating Factors With Chemotherapy: Opportunities for Cost Savings and Improved Outcomes
- (2011) A. L. Potosky et al. JNCI-Journal of the National Cancer Institute
- Risk of mortality in patients with cancer who experience febrile neutropenia
- (2010) Gary H. Lyman et al. CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More